Ricevi le ultime notizie sulle azioni Adaptimmune Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ADAP

Ultime notizie per

ADAPTIMMUNE THERAPEUTICS-ADR

Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

AdaptHealth Corp

Adaptive Hedged Multi-Asset Income ETF

Adaptive Alpha Opportunities ETF

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Core ETF

Adapti Inc

Adappter Token

Press Releases

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Adaptimmune Reports Q2 Financial Results and Provides Business Update

ADAP

AFFX

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

BioAtla

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Celularity

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

INmune Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Lantern Pharma

MAIA Biotechnology

Medicus Pharma

MediciNova

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Serina Therapeutics

Skye Bioscience

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

Comments

Adaptimmune Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO